Form 4: Regeneron EVP Van Plew Reports Stock Disposition

Regeneron Pharmaceuticals EVP Daniel P. Van Plew reported the disposition of 2,552 shares of common stock at $701.51 per share for tax withholding.

Summary

• Daniel P. Van Plew, Executive Vice President & General Manager, Industrial, at Regeneron Pharmaceuticals, Inc. (REGN), reported a transaction.
• On December 9, 2025, Van Plew disposed of 2,552 shares of Regeneron Common Stock.
• The disposition was made at a price of $701.51 per share.
• This transaction code 'F' typically indicates a disposition to the issuer to satisfy tax withholding obligations upon the vesting of restricted stock or the exercise of options.
• Following this transaction, Van Plew directly beneficially owns 21,673 shares of Common Stock.
• Additionally, Van Plew indirectly beneficially owns 12,376 shares through a 2025 GRAT and 1,129 shares through a 401(k) Plan.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider transaction for tax purposes, which is neutral in sentiment. It does not indicate any positive or negative operational or financial developments for the company.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing common across all publicly traded companies, reflecting an executive's management of their equity compensation, typically for tax obligations. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: This is a routine disclosure of an insider's stock transaction, which has minimal direct impact on the broader shareholder base. It reflects standard equity compensation management.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Insider Trading, Form 4, Stock Disposition, Daniel P. Van Plew, Executive Compensation, Tax Withholding